磷酸二酯酶抑制剂在心血管疾病中的潜在治疗作用的综合评价。

A comprehensive review on the potential therapeutic benefits of phosphodiesterase inhibitors on cardiovascular diseases.

机构信息

Pharmacological Research Center of Medicinal Plants, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Pharmacology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Medical Toxicology Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

出版信息

Biomed Pharmacother. 2017 Oct;94:541-556. doi: 10.1016/j.biopha.2017.07.084. Epub 2017 Aug 3.

DOI:10.1016/j.biopha.2017.07.084

PMID:28779712

Abstract

Phosphodiesterases are a group of enzymes that hydrolyze cyclic nucleotides, which assume a key role in directing intracellular levels of the second messengers' cAMP and cGMP, and consequently cell function. The disclosure of 11 isoenzyme families and our expanded knowledge of their functions at the cell and molecular level stimulate the improvement of isoenzyme selective inhibitors for the treatment of various diseases, particularly cardiovascular diseases. Hence, future and new mechanistic investigations and carefully designed clinical trials could help reap additional benefits of natural/synthetic PDE inhibitors for cardiovascular disease in patients. This review has concentrated on the potential therapeutic benefits of phosphodiesterase inhibitors on cardiovascular diseases.

摘要

磷酸二酯酶是一组能够水解环核苷酸的酶，在调节细胞内第二信使 cAMP 和 cGMP 的水平以及细胞功能方面发挥着关键作用。11 种同工酶家族的发现以及我们在细胞和分子水平上对其功能的深入了解，激发了人们开发同工酶选择性抑制剂来治疗各种疾病，特别是心血管疾病的积极性。因此，未来新的机制研究和精心设计的临床试验可能有助于为心血管疾病患者从天然/合成 PDE 抑制剂中获得更多益处。本综述集中讨论了磷酸二酯酶抑制剂在心血管疾病方面的潜在治疗益处。